Developer docs
API playgroundTry for free, no card

Search company profiles

Dexcom Ventures

Full company profile

uuid000adho

Namestring
Dexcom Ventures
Legal namestring
Dexcom Ventures
Company typeenum
Private
Founded yearint
2021
Descriptiontext

Dexcom Ventures is the corporate venture capital arm of Dexcom Inc. (NASDAQ: DXCM), a publicly-traded leader in continuous glucose monitoring technology. Founded circa 2021 and headquartered in San Diego alongside its parent, the fund is operated by a small team (1-10 employees) led by Managing Director Jason Halac and Analyst Adam Seivert, whose leadership draws on 20+ years of combined experience built inside Dexcom. Its stated mission is to invest in transformational technology platforms adjacent to or related to Dexcom's core diabetes care strategy, often through contrarian or symmetrical bets, in order to supplement growth in the parent company's core business while advancing development into chronic health conditions beyond diabetes.

Dexcom Ventures does not develop proprietary products or technology. Instead, it builds a portfolio of equity investments in early-stage healthcare technology companies, with six disclosed holdings: Medcrypt (medical device cybersecurity), Nutromics (Continuous Molecular Monitoring), Epitel (wearable seizure monitoring), Signos (AI-driven CGM app for weight management), BiointelliSense (medical-grade Remote Patient Monitoring Hospital at Home), and Beta Bionics (iLet Bionic Pancreas automated insulin delivery). Investment terms, check sizes, fund size, and round details are not publicly disclosed. The fund sources opportunities through technology scouting, strategic pipeline development, and co-investor networks, with deal flow sourced globally.

As a corporate venture subsidiary, Dexcom Ventures generates returns through equity realization events in portfolio companies — IPOs, acquisitions, or secondary sales — rather than recurring product or service revenue. Portfolio companies receive capital, strategic support, and access to Dexcom's distribution networks, regulatory expertise, and brand credibility, while Dexcom gains optionality on adjacent chronic-care and biosensing technologies. No AUM, management fees, carried interest, or realized returns are publicly disclosed for the entity.

Short descriptiontext

Dexcom Ventures is the corporate venture capital arm of Dexcom Inc., investing in early-stage healthcare technology companies in biosensing, remote monitoring, and chronic disease management adjacent to Dexcom's continuous glucose monitoring franchise. The San Diego-based fund backs startups globally with capital and strategic support.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
1–10
akta.pro rankint
HeadquartersSan Diego, United States
HQ citystring
San Diego
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
venture capital investing, healthcare technology investment, biosensing investment fund, chronic disease innovation, medical device investment
NAICS code2 codes
  • Portfolio Management and Investment Advice523940
  • Other Financial Vehicles52599
SIC code1 code
  • Finance Services6199
Product category
Healthcare Venture Capital
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Venture Capital Investment Returns
TypeSubscription Recurring
Description

As a corporate VC arm of Dexcom, the fund generates returns through equity investments in early-stage healthcare technology companies. Returns are realized through portfolio company exits via IPOs, acquisitions, or secondary sales, supplementing growth in Dexcom's core business while advancing development into chronic health conditions beyond diabetes.

dexcomventures.com
Marketing channels2 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 6 records shown
1Medcrypt
Description

Helping healthcare technology companies ensure medical devices are secure by design. Providing cybersecurity products and strategic management consulting to expedite the go-to-market process of medical device manufacturers' new life-saving connected technologies.

dexcomventures.com
+5 more records
Core offering1 text field

Dexcom Ventures is a corporate venture capital fund that invests equity capital in early-stage healthcare technology companies adjacent to or related to Dexcom's diabetes care strategy. The fund provides portfolio companies with capital investment, strategic partnership, and access to Dexcom's industry expertise, focusing on biosensing, data-driven healthcare, and chronic disease management platforms. Featured disclosed portfolio companies include Medcrypt, Nutromics, Epitel, Signos, BiointelliSense, and Beta Bionics.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Portfolio companies working to increase global access to timely health data for better healthcare and outcomes across populations
Product overview1 text field

Dexcom Ventures is a venture capital platform that invests in transformative technology companies in biosensing and data-driven healthcare. Rather than offering a unified product suite, it operates as an investment vehicle backing multiple distinct portfolio companies: Medcrypt (medical device cybersecurity), Nutromics (continuous molecular monitoring), Epitel (seizure monitoring wearables), Signos (AI-driven CGM app), BiointelliSense (remote patient monitoring), and Beta Bionics (iLet Bionic Pancreas insulin delivery). These investments are adjacent to or related to Dexcom's core diabetes care technology business.

Scale indicator2 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Largest and longest-running healthcare corporate venture arm, investing across medical devices, diagnostics, and digital health. Directly comparable to Dexcom Ventures as a strategic CVC using parent distribution, clinical, and regulatory assets to accelerate portfolio companies.

TypeDirect peer
Description

Roche's CVC arm focused on early-stage diagnostics and digital health. Closely analogous to Dexcom Ventures given the shared biosensing/diagnostics thesis and parent-company strategic backing model.

TypeDirect peer
Description

Historical CVC arm of Medtronic that invested in adjacent device, sensor, and digital health technologies. Highly comparable in thesis (device-adjacent strategic investing) to Dexcom Ventures, though now largely wound down.

4Bayer Leaps by Bayer
TypeDirect peer
Description

Bayer's CVC focused on breakthrough health and nutrition platforms with patient-level health-outcome orientation. Comparable as a large-pharma/strategic parent backing transformational health-tech platforms.

TypeDirect peer
Description

Long-standing CVC arm of Novartis investing in early-stage therapeutic and digital health companies. Comparable fund model — corporate-backed venture with strategic-plus-financial return orientation.

TypeDirect peer
Description

Sanofi's healthcare CVC that invests in early-stage biotech, digital health, and device-adjacent opportunities. Operates with a similar strategic-CVC playbook to Dexcom Ventures.

TypeDirect peer
Description

CVC arm of Boston Scientific targeting medical device adjacencies. Directly analogous as a medical-device parent's strategic investment vehicle.

TypeDirect peer
Description

CVC of Intuitive Surgical backing data-driven, minimally invasive care and digital surgery platforms. Comparable thesis around data-driven surgical/medical platforms adjacent to a category-leading parent.

TypeDirect peer
Description

Corporate venture arm of Becton Dickinson investing in high-growth medical device, diagnostics, and life sciences opportunities. Similar CVC model backing adjacent device and biosensing innovation.

TypeDirect peer
Description

Stryker's strategic investment arm backing medical device, digital health, and surgical innovation startups. Closely parallels Dexcom Ventures as a device-parent CVC investing in adjacent platforms.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment6 records

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Dexcom Ventures

Healthcare Venture Capitaldexcomventures.com

Dexcom Ventures is the corporate venture capital arm of Dexcom Inc., investing in early-stage healthcare technology companies in biosensing, remote monitoring, and chronic disease management adjacent to Dexcom's continuous glucose monitoring franchise. The San Diego-based fund backs startups globally with capital and strategic support.

What Dexcom Ventures does

Dexcom Ventures is the corporate venture capital arm of Dexcom Inc. (NASDAQ: DXCM), a publicly-traded leader in continuous glucose monitoring technology. Founded circa 2021 and headquartered in San Diego alongside its parent, the fund is operated by a small team (1-10 employees) led by Managing Director Jason Halac and Analyst Adam Seivert, whose leadership draws on 20+ years of combined experience built inside Dexcom. Its stated mission is to invest in transformational technology platforms adjacent to or related to Dexcom's core diabetes care strategy, often through contrarian or symmetrical bets, in order to supplement growth in the parent company's core business while advancing development into chronic health conditions beyond diabetes.

Dexcom Ventures does not develop proprietary products or technology. Instead, it builds a portfolio of equity investments in early-stage healthcare technology companies, with six disclosed holdings: Medcrypt (medical device cybersecurity), Nutromics (Continuous Molecular Monitoring), Epitel (wearable seizure monitoring), Signos (AI-driven CGM app for weight management), BiointelliSense (medical-grade Remote Patient Monitoring Hospital at Home), and Beta Bionics (iLet Bionic Pancreas automated insulin delivery). Investment terms, check sizes, fund size, and round details are not publicly disclosed. The fund sources opportunities through technology scouting, strategic pipeline development, and co-investor networks, with deal flow sourced globally.

As a corporate venture subsidiary, Dexcom Ventures generates returns through equity realization events in portfolio companies — IPOs, acquisitions, or secondary sales — rather than recurring product or service revenue. Portfolio companies receive capital, strategic support, and access to Dexcom's distribution networks, regulatory expertise, and brand credibility, while Dexcom gains optionality on adjacent chronic-care and biosensing technologies. No AUM, management fees, carried interest, or realized returns are publicly disclosed for the entity.

Dexcom Ventures firmographics

Firmographics
Name
Dexcom Ventures
Legal name
Dexcom Ventures
Website
https://dexcomventures.com
Company type
Private
Founded year
2021
Operating status
Operating
Headcount range
1–10 employees
Short description
Dexcom Ventures is the corporate venture capital arm of Dexcom Inc., investing in early-stage healthcare technology companies in biosensing, remote monitoring, and chronic disease management adjacent to Dexcom's continuous glucose monitoring franchise. The San Diego-based fund backs startups globally with capital and strategic support.
Ownership category
akta.pro rank

Where Dexcom Ventures is headquartered

Location

Headquarters

HQ city
San Diego
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Dexcom Ventures business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Marketing or Sales, Others

Revenue model

  1. Venture Capital Investment Returns: As a corporate VC arm of Dexcom, the fund generates returns through equity investments in early-stage healthcare technology companies. Returns are realized through portfolio company exits via IPOs, acquisitions, or secondary sales, supplementing growth in Dexcom's core business while advancing development into chronic health conditions beyond diabetes.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Dexcom Ventures product offering

Product offering

Core offering

Dexcom Ventures is a corporate venture capital fund that invests equity capital in early-stage healthcare technology companies adjacent to or related to Dexcom's diabetes care strategy. The fund provides portfolio companies with capital investment, strategic partnership, and access to Dexcom's industry expertise, focusing on biosensing, data-driven healthcare, and chronic disease management platforms. Featured disclosed portfolio companies include Medcrypt, Nutromics, Epitel, Signos, BiointelliSense, and Beta Bionics.

Product overview

Dexcom Ventures is a venture capital platform that invests in transformative technology companies in biosensing and data-driven healthcare. Rather than offering a unified product suite, it operates as an investment vehicle backing multiple distinct portfolio companies: Medcrypt (medical device cybersecurity), Nutromics (continuous molecular monitoring), Epitel (seizure monitoring wearables), Signos (AI-driven CGM app), BiointelliSense (remote patient monitoring), and Beta Bionics (iLet Bionic Pancreas insulin delivery). These investments are adjacent to or related to Dexcom's core diabetes care technology business.

Differentiator

Problem solved

Functional benefit

Brands

  • Medcrypt: Helping healthcare technology companies ensure medical devices are secure by design. Providing cybersecurity products and strategic management consulting to expedite the go-to-market process of medical device manufacturers' new life-saving connected technologies.
  • Nutromics
  • Epitel
  • Signos
  • BiointelliSense
  • Beta Bionics

Quantifiable outcome

  • Portfolio companies working to increase global access to timely health data for better healthcare and outcomes across populations

Companies that use Dexcom Ventures

Customer profile

Segments1 record

Ideal customer profiles1 record

Dexcom Ventures technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Dexcom Ventures partnerships and signals

Strategic signal

Scale indicators2 records

Recent moves6 records

Expansion highlights5 records

Dexcom Ventures competitors and assessment

Company assessment

Direct peers

  • Johnson & Johnson Innovation (JJDC): Largest and longest-running healthcare corporate venture arm, investing across medical devices, diagnostics, and digital health. Directly comparable to Dexcom Ventures as a strategic CVC using parent distribution, clinical, and regulatory assets to accelerate portfolio companies.
  • Roche Venture Fund: Roche's CVC arm focused on early-stage diagnostics and digital health. Closely analogous to Dexcom Ventures given the shared biosensing/diagnostics thesis and parent-company strategic backing model.
  • Medtronic Ventures: Historical CVC arm of Medtronic that invested in adjacent device, sensor, and digital health technologies. Highly comparable in thesis (device-adjacent strategic investing) to Dexcom Ventures, though now largely wound down.
  • Bayer Leaps by Bayer: Bayer's CVC focused on breakthrough health and nutrition platforms with patient-level health-outcome orientation. Comparable as a large-pharma/strategic parent backing transformational health-tech platforms.
  • Novartis Venture Fund: Long-standing CVC arm of Novartis investing in early-stage therapeutic and digital health companies. Comparable fund model — corporate-backed venture with strategic-plus-financial return orientation.
  • Sanofi Ventures: Sanofi's healthcare CVC that invests in early-stage biotech, digital health, and device-adjacent opportunities. Operates with a similar strategic-CVC playbook to Dexcom Ventures.
  • Boston Scientific Ventures: CVC arm of Boston Scientific targeting medical device adjacencies. Directly analogous as a medical-device parent's strategic investment vehicle.
  • Intuitive Ventures: CVC of Intuitive Surgical backing data-driven, minimally invasive care and digital surgery platforms. Comparable thesis around data-driven surgical/medical platforms adjacent to a category-leading parent.
  • BD (Becton Dickinson) Ventures: Corporate venture arm of Becton Dickinson investing in high-growth medical device, diagnostics, and life sciences opportunities. Similar CVC model backing adjacent device and biosensing innovation.
  • Stryker Corporate Development / Ventures: Stryker's strategic investment arm backing medical device, digital health, and surgical innovation startups. Closely parallels Dexcom Ventures as a device-parent CVC investing in adjacent platforms.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

Dexcom Ventures financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Dexcom Ventures leadership team

Management profile

Number of profiles

Profiles2 records

Dexcom Ventures funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Dexcom Ventures M&A and investment

M&A and investment

M&A

Investments6 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Dexcom Ventures

What does Dexcom Ventures do?

Dexcom Ventures is a corporate venture capital fund that invests equity capital in early-stage healthcare technology companies adjacent to or related to Dexcom's diabetes care strategy. The fund provides portfolio companies with capital investment, strategic partnership, and access to Dexcom's industry expertise, focusing on biosensing, data-driven healthcare, and chronic disease management platforms. Featured disclosed portfolio companies include Medcrypt, Nutromics, Epitel, Signos, BiointelliSense, and Beta Bionics.

Is Dexcom Ventures a public or private company?

Dexcom Ventures is a private company. It is classified as corporate owned and is currently operating.

When was Dexcom Ventures founded?

Dexcom Ventures was founded in 2021. It employs 1 to 10 people.

Where is Dexcom Ventures based?

Dexcom Ventures is headquartered in San Diego, United States, in the North America region.

How does Dexcom Ventures make money?

One revenue line is on record: venture Capital Investment Returns.

Who are Dexcom Ventures's main competitors?

Direct peers on record are Johnson & Johnson Innovation (JJDC), Roche Venture Fund, Medtronic Ventures, Bayer Leaps by Bayer, Novartis Venture Fund, Sanofi Ventures, Boston Scientific Ventures, Intuitive Ventures, BD (Becton Dickinson) Ventures and Stryker Corporate Development / Ventures.

Does Dexcom Ventures have an API?

No public API is recorded for Dexcom Ventures.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Pulse 2.0myBiometry: Asthma And COPD Diagnostic Company Raises $5 Million (Seed)myBiometry raised $5 million in seed funding led by Dexcom Ventures, with participation from CareSource Indiana and others. The funds will advance its fenoTRACK breath test, which measures type 2 airway inflammation and reduces exacerbation risk by 38-50%. The company is preparing for regulatory submission.Business Wire BlogmyBiometry Raises $5 Million in Oversubscribed Seed Round to Advance Next-Generation Asthma and COPD CaremyBiometry raised $5 million in an oversubscribed seed round led by Dexcom Ventures, with participation from CareSource Indiana and Elevate Ventures. The funding will advance its fenoTRACK device, which measures type 2 airway inflammation to detect asthma and COPD exacerbations. The company is preparing for regulatory submission.CNBCAs Ozempic and Wegovy take off, this tech startup just raised $20 million to tackle weight loss with dataSignos, a weight-loss startup, raised $20 million led by Cheyenne Ventures and GV. The company uses Dexcom CGMs to provide real-time diet and exercise recommendations. It plans to expand its team and research into metabolic health.PR NewswireMedCrypt Extends Series B with Additional Investment from Dexcom VenturesMedCrypt announced additional funding from Dexcom Ventures, extending its Series B round. The company's total funding now stands at $36.4 million, with the new funds used to grow its engineering team for medical device cybersecurity. The global wearable medical device market is valued at $21.3 billion and expected to grow 28% by 2030.Venture Capital Access OnlineMedCrypt Extends Series B with Additional Investment from Dexcom VenturesMedCrypt, a cybersecurity solution provider for medical devices, announced additional investment from Dexcom Ventures to expand its engineering team and meet growing demand for secure solutions. This funding extends MedCrypt's Series B round, increasing total funding to $36.4 million, and reflects the importance of cybersecurity in healthcare. MedCrypt serves major medical device manufacturers and aims to enhance security for connected technologies in compliance with FDA requirements.MobiHealthNewsLab-on-a-patch maker Nutromics scores $14M from Dexcom Ventures, othersMedtech startup Nutromics has secured a $14 million investment from strategic investors including Dexcom Ventures, VU Venture Partners, and Artesian Investments. The company plans to use the funds to advance clinical studies for its lab-in-a-patch diagnostic platform and expand its research teams in Australia and the United States.DrugdeliverybusinessDexcom promotes Jereme Sylvain to CFODexcom promoted Jereme Sylvain to EVP and CFO, effective immediately. He will report to COO Quentin Blackford, who will now also oversee strategy and corporate development. Sylvain joined Dexcom in 2018 as SVP of finance and chief accounting officer.San Diego Business JournalDexcom Launches Venture ArmDexcom launched Dexcom Ventures, its first corporate venture capital fund, to invest in glucose sensing and metabolic monitoring companies. The fund will be solely Dexcom's undertaking, with no additional limited partners, and will evaluate early and later stage startups. Initial investment size was not disclosed.